Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
November 6, 2019
— Third-Quarter 2019 Net Sales of $335.5 Million Increased 3 Percent;
Third-Quarter 2019 GAAP Net Income of $18.2 Million; Adjusted EBITDA of $130.4 Million —
— Record Quarterly Orphan and Rheumatology Segment Net Sales of $250.4 Million, an Increase
of 14 Percent; Segment Represents Approximately 75 Percent of Total Company Net Sales;
KRYSTEXXA® Third-Quarter 2019 Net Sales of $99.6 Million Increased 42 Percent —
— Maintaining Full-Year 2019 Net Sales Guidance Range of $1.28 to $1.30 Billion;
Raising Midpoint of Full-Year 2019 Adjusted EBITDA Guidance; Range is Now
$465 Million to $475 Million;
KRYSTEXXA Full-Year 2019 Net Sales Growth Expected to Be Greater Than 25 Percent —
— Granted U.S. FDA Priority Review of Teprotumumab with March 8, 2020, PDUFA Date —
— Initiated PROTECT Trial Evaluating KRYSTEXXA to Improve Management of
Uncontrolled Gout for Adults with a Kidney Transplant —
— Presented Phase 3 Teprotumumab Secondary Endpoint Data Demonstrating Significantly Reduced
Double Vision and Improved Quality of Life for Active Thyroid Eye Disease (TED) Patients —
— Cash Position of $884 Million; Net Leverage of 1.1 Times as of Sept. 30, 2019 —
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced its third-quarter 2019 financial results and raised the midpoint of its full-year 2019 adjusted EBITDA guidance.
“Our third-quarter performance underscores the strength of our commercial and R&D organizations,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We generated record quarterly net sales in our orphan and rheumatology segment – including a record quarter for net sales of KRYSTEXXA, our medicine for uncontrolled gout – and the U.S. FDA also granted Priority Review of our BLA for teprotumumab, our biologic candidate for the treatment of active thyroid eye disease. We made great progress on all fronts during the quarter, including our market education activities related to teprotumumab, and remain excited about the prospect of being able to address the significant unmet need for patients living with active thyroid eye disease.”
Financial Highlights
| (in millions except for per share amounts and percentages) | Q3 19 | Q3 18 | % Change | YTD 19 | YTD 18 | % Change | |||||||||||||
| Net sales |
$ |
335.5 |
$ |
325.3 |
3 |
|
$ |
936.5 |
|
$ |
852.0 |
|
10 |
||||||
| Net income (loss) |
|
18.2 |
|
33.4 |
(45 |
) |
|
(19.7 |
) |
|
(140.0 |
) |
86 |
||||||
| Non-GAAP net income |
|
124.1 |
|
112.6 |
10 |
|
|
273.6 |
|
|
197.9 |
|
38 |
||||||
| Adjusted EBITDA |
|
130.4 |
|
149.9 |
(13 |
) |
|
342.9 |
|
|
300.3 |
|
14 |
||||||
| Earnings (Loss) per share – diluted |
|
0.09 |
|
0.19 |
(53 |
) |
|
(0.11 |
) |
|
(0.84 |
) |
87 |
||||||
| Non-GAAP earnings per share – diluted |
|
0.64 |
|
0.65 |
(2 |
) |
|
1.44 |
|
|
1.16 |
|
24 |
||||||
Third-Quarter and Recent Company Highlights
- Granted Priority Review of Teprotumumab BLA: In September, the Company announced the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its investigational medicine teprotumumab for the treatment of active TED and granted it Priority Review designation, with a March 8, 2020, Prescription Drug User Fee Act (PDUFA) date. If approved, teprotumumab would be the first and only approved treatment for active TED.
- Presented Additional Teprotumumab Phase 3 Data: The Company recently presented additional data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active TED compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical activity score (CAS). At Week 24, 68 percent of teprotumumab patients had a change from baseline of at least 1 grade in diplopia, compared to 29 percent of placebo patients (p=0.001). On the Graves’ Ophthalmopathy Quality of Life (GO-QoL) scale, a change of 6 points is considered clinically significant, and teprotumumab patients had a mean change of 13.79 compared to 4.43 for placebo patients (p<0.001). At Week 24, 59 percent of teprotumumab patients achieved a CAS value of 0 or 1 compared to 21 percent of placebo patients (p<0.001). These data were presented during the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium in San Francisco, and build upon data presented earlier in the year that demonstrated the significant benefit of teprotumumab on proptosis.
- Announced Teprotumumab Expanded Access Program (EAP): In August, the Company announced an EAP for teprotumumab while the FDA reviews the BLA. The EAP provides access to teprotumumab for patients with active TED who meet protocol criteria, who may have otherwise progressed to the inactive stage of the debilitating disease before the BLA review process is completed.
- Initiated PROTECT Trial Evaluating KRYSTEXXA to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant: In October, the Company initiated its open-label PROTECT clinical trial evaluating the use of KRYSTEXXA in adults with uncontrolled gout who have undergone a kidney transplant. The objective of the trial is to demonstrate that KRYSTEXXA provides effective disease control without burdening the kidneys. The randomized multicenter open-label trial is expected to enroll 20 adults with uncontrolled gout who have received a kidney transplant.
- Further Improved the Company’s Capital Structure: In July, the Company issued $600 million of 5.5 percent Senior Notes due 2027 and used the proceeds together with cash on hand to repay $625 million of its outstanding debt. These actions reduced interest expense and extended the maturity of the debt, furthering the Company’s strategy to improve its capital structure. The Company has reduced its gross debt by $575 million in the year-to-date period ended Sept. 30, 2019.
- Intellectual Property Update: In October, the Federal Circuit Court of Appeals issued a decision in favor of the Company regarding an appeal of the 2017 decision by the United States District Court for the District of New Jersey upholding the validity of a PENNSAID® 2% patent that expires in 2027.
- Gender and Ethnicity Pay Equity Demonstrated; Received Best Medium Workplace Award: A recent study conducted by Aon, a leading compensation consulting firm, showed that Horizon demonstrates both gender and ethnicity pay equity, ranking in the top five of the roughly 100 companies Aon has studied in this regard, and in line with the value the Company places on diversity. In addition, the Company was selected to FORTUNE Magazine’s 2019 “Best Medium Workplaces” list for the fourth consecutive year, ranking eighth out of 100 other medium sized companies.
- Appointed Sue Mahony to the Board of Directors: In August, the Company appointed Sue Mahony, Ph.D., MBA, to its board of directors. Dr. Mahony brings more than 30 years of diverse industry experience to the board, including an 18-year tenure at Eli Lilly and Company, where she served in a variety of global and domestic leadership roles of increasing responsibility, including helping oversee the development of an innovative pipeline. Before Lilly, Dr. Mahony spent five years at Bristol-Myers Squibb Company.
- Named Andy Pasternak Executive Vice President, Chief Business Officer: In August, the Company named Andy Pasternak executive vice president, chief business officer, effective Nov. 1. Pasternak leads business development, mergers and acquisitions, corporate strategy, commercial development and portfolio management.
Research and Development Programs
Orphan Disease Candidate and Program:
- Teprotumumab: Teprotumumab is a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor candidate for the treatment of active TED. TED is a serious, progressive, vision-threatening autoimmune disease in which the muscles and fatty tissue behind the eye become inflamed and expand, which can lead to proptosis (eye bulging) and diplopia (double vision) and impact activities of daily living and quality of life. The development program for teprotumumab in TED includes positive results from the confirmatory Phase 3 OPTIC clinical trial, announced in February 2019, as well as positive Phase 2 results published in The New England Journal of Medicine in May 2017. The OPTIC study met its primary endpoint of a ≥2 mm reduction in proptosis (p<0.001), the main cause of morbidity in TED, with 82.9 percent of patients treated with teprotumumab demonstrating a significant improvement in proptosis compared to 9.5 percent of placebo patients. In addition, all secondary endpoints were met (p≤0.001), and the safety profile was consistent with the Phase 2 study.
Rheumatology Pipeline Candidates and Programs:
- KRYSTEXXA MIRROR Immunomodulation Trial: The Company is evaluating the use of methotrexate to increase the response rate with KRYSTEXXA. This evaluation was initiated through the small open-label MIRROR pilot study, followed by the larger MIRROR registrational clinical trial. Methotrexate is the immunomodulator most used by rheumatologists, and has been shown to reduce anti-drug antibody formation to biologic therapies when used in conjunction with these therapies. The MIRROR registrational trial commenced in June.
- KRYSTEXXA PROTECT Trial in Kidney Transplant Patients with Uncontrolled Gout: In October, the Company initiated PROTECT, its clinical trial evaluating the effect of KRYSTEXXA on serum uric acid levels in kidney transplant patients with uncontrolled gout. Kidney transplant patients have more than a tenfold increase in the prevalence of gout when compared to the general population, and literature suggests that persistently high serum uric acid levels can be associated with organ rejection. Managing uncontrolled gout is one of the most common and significant unmet needs of kidney transplant patients.
- Next-generation Programs for Uncontrolled Gout: The Company is pursuing early-stage development programs for next-generation biologics for uncontrolled gout to support and sustain the Company’s market leadership in this area. These include HZN-003 and HZN-007, as well as a collaboration with HemoShear Therapeutics, LLC (HemoShear) to discover new targets for gout.
Third-Quarter Financial Results
Note: For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release.
- Net Sales: Third-quarter 2019 net sales were $335.5 million, an increase of 3 percent.
- Gross Profit: Under U.S. GAAP, the third-quarter 2019 gross profit ratio was 73.2 percent compared to 72.0 percent in the third quarter of 2018. The non-GAAP gross profit ratio in the third quarter of 2019 was 90.7 percent compared to 91.2 percent in the third quarter of 2018.
- Operating Expenses: Research and development (R&D) expenses were 7.3 percent of net sales and selling, general and administrative (SG&A) expenses were 51.4 percent of net sales. Non-GAAP R&D expenses were 5.8 percent of net sales, and non-GAAP SG&A expenses were 46.2 percent of net sales.
- Income Tax Rate: In the third quarter of 2019, the income tax rates on a GAAP and non-GAAP basis were 247.9 percent and negative 7.5 percent, respectively.
- Net Income: On a GAAP basis in the third quarter of 2019, net income was $18.2 million. Third-quarter 2019 non-GAAP net income was $124.1 million.
- Adjusted EBITDA: Third-quarter 2019 adjusted EBITDA was $130.4 million.
- Earnings per Share: On a GAAP basis, diluted earnings per share in the third quarter of 2019 and 2018 were $0.09 and $0.19, respectively. Non-GAAP diluted earnings per share in the third quarter of 2019 and 2018 were $0.64 and $0.65, respectively. Weighted average shares outstanding used for calculating GAAP and non-GAAP diluted earnings per share in the third quarter of 2019 were 194.2 million.
Third-Quarter Segment Results
Management uses net sales and segment operating income to evaluate the performance of the Company’s two segments. While segment operating income contains certain adjustments to the directly comparable GAAP figures in the Company’s consolidated financial results, it is considered to be prepared in accordance with GAAP for purposes of presenting the Company’s segment operating results.
Orphan and Rheumatology Segment
| (in millions except for percentages) | Q3 19 | Q3 18 | % Change | YTD 19 | YTD 18 | % Change | |||||||||||||
| KRYSTEXXA |
|
99.6 |
|
70.2 |
42 |
|
|
231.6 |
|
175.6 |
32 |
|
|||||||
| RAVICTI®(1) |
|
60.0 |
|
60.4 |
(1 |
) |
|
160.3 |
|
166.5 |
(4 |
) |
|||||||
| PROCYSBI® |
|
40.4 |
|
41.4 |
(2 |
) |
|
121.1 |
|
114.7 |
6 |
|
|||||||
| ACTIMMUNE® |
|
27.9 |
|
25.8 |
8 |
|
|
78.9 |
|
78.1 |
1 |
|
|||||||
| RAYOS® |
|
19.3 |
|
17.2 |
13 |
|
|
59.1 |
|
41.3 |
43 |
|
|||||||
| BUPHENYL®(1) |
|
3.0 |
|
4.4 |
(30 |
) |
|
8.2 |
|
15.3 |
(47 |
) |
|||||||
| QUINSAIRTM |
|
0.2 |
|
0.1 |
67 |
|
|
0.6 |
|
0.3 |
59 |
|
|||||||
| LODOTRA®(1) |
|
– |
|
0.4 |
NM |
|
|
– |
|
2.0 |
NM |
|
|||||||
| Orphan and Rheumatology Net Sales |
$ |
250.4 |
$ |
219.9 |
14 |
|
$ |
659.8 |
$ |
593.8 |
11 |
|
|||||||
| Orphan and Rheumatology Segment Operating Income |
$ |
89.8 |
$ |
91.5 |
(2 |
) |
$ |
211.0 |
$ |
205.3 |
3 |
|
|||||||
|
(1) |
Beginning in 2019, the Company no longer recognizes revenue from RAVICTI and AMMONAPS sales outside of North America and Japan, nor from sales of LODOTRA. On Dec. 28, 2018, the Company divested the rights to RAVICTI and AMMONAPS outside of North America and Japan. AMMONAPS is known as BUPHENYL in the United States. In addition, effective Jan. 1, 2019, the RAYOS and LODOTRA license and supply agreements were amended, including the transfer of LODOTRA to Vectura Group plc. LODOTRA is known as RAYOS in the United States. |
- Third-quarter 2019 net sales of the orphan and rheumatology segment, the Company’s strategic growth segment, were $250.4 million, an increase of 14 percent over the prior year’s quarter, driven by growth of KRYSTEXXA, ACTIMMUNE and RAYOS. The orphan and rheumatology segment represents approximately 75 percent of total Company net sales.
- Third-quarter 2019 orphan and rheumatology segment operating income was $89.8 million, which includes the impact of investment in teprotumumab pre-launch activities.
Inflammation Segment
| (in millions except for percentages) | Q3 19 | Q3 18 | % Change | YTD 19 | YTD 18 | % Change | ||||||||||||
| PENNSAID 2% |
|
42.1 |
|
51.5 |
(18 |
) |
|
143.7 |
|
125.9 |
14 |
|
||||||
| DUEXIS® |
|
29.9 |
|
34.2 |
(13 |
) |
|
89.4 |
|
80.6 |
11 |
|
||||||
| VIMOVO® |
|
13.1 |
|
18.6 |
(30 |
) |
|
41.8 |
|
48.9 |
(15 |
) |
||||||
| MIGERGOT®(1) |
|
– |
|
1.1 |
NM |
|
|
1.8 |
|
2.8 |
(34 |
) |
||||||
| Inflammation Net Sales |
$ |
85.1 |
$ |
105.4 |
(19 |
) |
$ |
276.7 |
$ |
258.2 |
7 |
|
||||||
| Inflammation Segment Operating Income |
$ |
39.6 |
$ |
58.0 |
(32 |
) |
$ |
130.8 |
$ |
94.3 |
39 |
|
||||||
|
(1) |
In June 2019, the Company divested the rights to MIGERGOT. |
- Third-quarter 2019 net sales of the inflammation segment were $85.1 million and segment operating income was $39.6 million.
Cash Flow Statement and Balance Sheet Highlights
- On a GAAP basis in the third quarter of 2019, operating cash flow was $87.5 million. Non-GAAP operating cash flow was $96.5 million.
- The Company had cash and cash equivalents of $884.0 million as of Sept. 30, 2019.
-
In July, the Company issued $600 million of 5.5 percent Senior Notes due 2027 and used the proceeds along with cash on hand to repay $625 million of its outstanding debt.
As of Sept. 30, 2019, the total principal amount of debt outstanding was $1.418 billion, consisting of $418 million in senior secured term loans due 2026, $600 million of Senior Notes due 2027 and $400 million of Exchangeable Senior Notes due 2022. As of Sept. 30, 2019, net debt was $534.1 million and net-debt-to-last-12-months adjusted EBITDA leverage ratio was 1.1 times, compared to 2.9 times at Sept. 30, 2018.
2019 Guidance
The Company continues to expect full-year 2019 net sales to range between $1.28 billion and $1.30 billion. The Company now expects full-year 2019 adjusted EBITDA to range between $465 million and $475 million, versus the previous guidance range of $460 million to $475 million.
Webcast
At 8 a.m. EDT / 1 p.m. IST today, the Company will host a live webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.
About Horizon
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Note Regarding Use of Non-GAAP Financial Measures
EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon as non-GAAP financial measures. Horizon provides certain other financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax rate, non-GAAP operating cash flow, net leverage ratio and net debt, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures as well as EBITDA exclude acquisition and/or divestiture-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, gain or loss from sale of assets, upfront, progress and milestone payments related to license and collaboration agreements, litigation settlements, loss on debt extinguishment, costs of debt refinancing, drug manufacturing harmonization costs, restructuring and realignment costs, as well as non-cash items such as share-based compensation, depreciation and amortization, non-cash interest expense, long-lived asset impairment charges and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected 2019 financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company’s performance. For example, adjusted EBITDA is used by Horizon as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided a reconciliation of its full-year 2019 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon’s stock price, the variability associated with the size or timing of acquisitions/divestitures and other factors. These components of net income (loss) could significantly impact Horizon’s actual net income (loss).
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to Horizon’s full-year 2019 net sales and adjusted EBITDA guidance; expected financial performance and operating results in future periods, including potential growth in net sales of certain of Horizon’s medicines; expected impact of refinancing transactions; expected timing of clinical trials and regulatory submissions and decisions, including related to the BLA for teprotumumab; potential market opportunity for and benefits of Horizon’s medicines and medicine candidates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon’s ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates, such as teprotumumab, and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.
|
Contacts: |
|
|
|
|
|
|
|
Investors: |
U.S. Media: |
|
|
Tina Ventura |
Geoff Curtis |
|
|
Senior Vice President, |
Executive Vice President, |
|
|
Investor Relations |
Corporate Affairs & Chief Communications Officer |
|
|
|
|
|
|
Ruth Venning |
Ireland Media: |
|
|
Executive Director, |
Ray Gordon |
|
|
Investor Relations |
Gordon MRM |
|
| Horizon Therapeutics plc | ||||||||||||||||||||
| Condensed Consolidated Statements of Operations (Unaudited) | ||||||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
||||||
| Net sales |
$ |
335,466 |
|
$ |
325,311 |
|
$ |
936,484 |
|
$ |
852,027 |
|
||||||||
| Cost of goods sold |
|
89,949 |
|
|
91,077 |
|
|
267,254 |
|
|
292,702 |
|
||||||||
| Gross profit |
|
245,517 |
|
|
234,234 |
|
|
669,230 |
|
|
559,325 |
|
||||||||
| OPERATING EXPENSES: | ||||||||||||||||||||
| Research and development |
|
24,572 |
|
|
21,169 |
|
|
74,611 |
|
|
63,079 |
|
||||||||
| Selling, general and administrative |
|
172,326 |
|
|
161,585 |
|
|
511,720 |
|
|
517,858 |
|
||||||||
| (Gain)/Loss on sale of assets |
|
– |
|
|
(12,303 |
) |
|
10,963 |
|
|
(12,303 |
) |
||||||||
| Impairment of long-lived assets |
|
– |
|
|
1,603 |
|
|
– |
|
|
35,249 |
|
||||||||
| Total operating expenses |
|
196,898 |
|
|
172,054 |
|
|
597,294 |
|
|
603,883 |
|
||||||||
| Operating income (loss) |
|
48,619 |
|
|
62,180 |
|
|
71,936 |
|
|
(44,558 |
) |
||||||||
| OTHER EXPENSE, NET: | ||||||||||||||||||||
| Interest expense, net |
|
(20,428 |
) |
|
(30,437 |
) |
|
(69,991 |
) |
|
(91,921 |
) |
||||||||
| Loss on debt extinguishment |
|
(41,371 |
) |
|
– |
|
|
(58,835 |
) |
|
– |
|
||||||||
| Foreign exchange (loss) gain |
|
(40 |
) |
|
35 |
|
|
(25 |
) |
|
(81 |
) |
||||||||
| Other income (expense), net |
|
890 |
|
|
337 |
|
|
(193 |
) |
|
834 |
|
||||||||
| Total other expense, net |
|
(60,949 |
) |
|
(30,065 |
) |
|
(129,044 |
) |
|
(91,168 |
) |
||||||||
| (Loss) Income before (benefit) expense for income taxes |
|
(12,330 |
) |
|
32,115 |
|
|
(57,108 |
) |
|
(135,726 |
) |
||||||||
| (Benefit) expense for income taxes |
|
(30,564 |
) |
|
(1,266 |
) |
|
(37,359 |
) |
|
4,301 |
|
||||||||
| Net income (loss) |
$ |
18,234 |
|
$ |
33,381 |
|
$ |
(19,749 |
) |
$ |
(140,027 |
) |
||||||||
| Earnings (Loss) per ordinary share – basic |
$ |
0.10 |
|
$ |
0.20 |
|
$ |
(0.11 |
) |
$ |
(0.84 |
) |
||||||||
| Weighted average ordinary shares outstanding – basic |
|
186,470,141 |
|
|
167,047,104 |
|
|
181,949,838 |
|
|
166,018,603 |
|
||||||||
| Earnings (Loss) per ordinary share – diluted |
$ |
0.09 |
|
$ |
0.19 |
|
$ |
(0.11 |
) |
$ |
(0.84 |
) |
||||||||
| Weighted average ordinary shares outstanding – diluted |
|
194,171,967 |
|
|
172,485,757 |
|
|
181,949,838 |
|
|
166,018,603 |
|
||||||||
Contacts
Investors:
Tina Ventura
Senior Vice President,
Investor Relations
[email protected]
Ruth Venning
Executive Director,
Investor Relations
[email protected]
U.S. Media:
Geoff Curtis
Executive Vice President,
Corporate Affairs & Chief Communications Officer
[email protected]
Ireland Media:
Ray Gordon
Gordon MRM
[email protected]